Soligenix announces publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses

Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses princeton, n.j. , jan. 2, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both sudan ebolavirus (sudv) and marburg marburgvirus (marv) infections.
SNGX Ratings Summary
SNGX Quant Ranking